Related MeSH Hierarchy (6)
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Nerve Tissue » Nerve Sheath Neoplasms » Neurofibroma » Neurofibromatoses
Diseases [C] » Neoplasms [C04] » Neoplastic Syndromes, Hereditary » Neurofibromatoses
Diseases [C] » Nervous System Diseases [C10] » Neurocutaneous Syndromes » Neurofibromatoses
Diseases [C] » Nervous System Diseases [C10] » Neurodegenerative Diseases » Heredodegenerative Disorders, Nervous System » Neurofibromatoses
Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Genetic Diseases, Inborn » Heredodegenerative Disorders, Nervous System » Neurofibromatoses
Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Genetic Diseases, Inborn » Neoplastic Syndromes, Hereditary » Neurofibromatoses
Description
A group of disorders characterized by an autosomal dominant pattern of inheritance with high rates of spontaneous mutation and multiple neurofibromas or neurilemmomas. NEUROFIBROMATOSIS 1 (generalized neurofibromatosis) accounts for approximately 95% of cases, although multiple additional subtypes (e.g., NEUROFIBROMATOSIS 2, neurofibromatosis 3, etc.) have been described. (From Neurochirurgie 1998 Nov;44(4):267-72) MeSH
Hierarchy View
Subtype Terms (2)
Neurofibromatosis 1
51 drugs (42 approved, 9 experimental)
Neurofibromatosis 2
18 drugs (12 approved, 6 experimental)
Approved Indicated Drugs (1)
Phase 4 Indicated Drugs (6)
Phase 3 Indicated Drugs (1)
Phase 2 Indicated Drugs (5)
Phase 1 Indicated Drugs (5)
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (5)
Organization Involved with Phase 2 Indications (61)
Betta Pharmaceuticals Co.,Ltd.
Children's National Medical Center
Memorial Sloan-Kettering Cancer Center
National Institutes of Health (NIH)
Simcere Pharmaceutical Co., Ltd
SpringWorks Therapeutics, Inc.
Texas Neurofibromatosis Foundation
The Children's Tumor Foundation
The Pacific Pediatric Neuro-Oncology Consortium
The University of Texas, Dallas
University of Alabama, Birmingham
University of British Columbia
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.